Algert Global’s Generation Bio GBIO Stock Holding History

Algert Global’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,775	Closed	-$147K	–	1176
2022 Q3	$147K	Buy	+2,775	New	+$174K	0.01%	1073

Other funds holding GBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Algert Global's GBIO Position: Q4 2022 in Review

Algert Global sold out of Generation Bio (GBIO) in Q4 2022, closing a stake of 2,775 shares — an estimated $147K sold.

Algert Global first reported a position in GBIO in Q3 2022 and held it in 1 quarter. The position peaked at $147K in Q3 2022. 95 funds tracked by Wall St. Rank hold GBIO as of Q4 2022.

Algert Global reported no remaining Generation Bio position as of Q4 2022 after selling out during the quarter.
Algert Global sold 2,775 Generation Bio shares in Q4 2022, an estimated $147K.
Algert Global first reported a position in Generation Bio in Q3 2022 and held it in 1 quarter.
Algert Global's Generation Bio position peaked at $147K in Q3 2022.
95 funds tracked by Wall St. Rank held Generation Bio as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.